Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

815
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
815
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

578
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
578
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

281
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
281
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

338
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
338
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

250
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
250
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

548
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
548

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaping and vascular health: emerging risks for Raynaud's, chilblains and Buerger's disease.

Rheumatology (Oxford, England)·2026
Same author

Metabolism and excretion pathways of CD388, a novel drug-fragment crystallizable conjugate for prevention of seasonal or pandemic influenza.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Systemic sclerosis-associated pulmonary arterial hypertension and pulmonary fibrosis: exploring biomarker discriminators with advanced omics in a Caucasian cohort.

Frontiers in immunology·2026
Same author

Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis.

Annals of the rheumatic diseases·2026
Same author

Evaluation of an <i>in vivo</i> pulmonary aspergillosis model for triazole susceptibility breakpoint development.

Antimicrobial agents and chemotherapy·2026
Same author

A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers.

Clinical pharmacology in drug development·2026

Related Experiment Video

Updated: Feb 13, 2026

Cell Population Analyses During Skin Carcinogenesis
06:53

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

13.0K

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data.

Elizabeth A Lakota1, Voon Ong2, Shawn Flanagan2

  • 1Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA elakota@icpd.com.

Antimicrobial Agents and Chemotherapy
|March 21, 2018
PubMed
Summary

Rezafungin, a novel antifungal, shows potent activity against Candida infections. A population pharmacokinetic model was developed to understand its drug disposition, aiding future dosing decisions.

Keywords:
echinocandinpharmacokineticspopulation pharmacokinetics

More Related Videos

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
11:10

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Published on: December 27, 2010

12.8K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.9K

Related Experiment Videos

Last Updated: Feb 13, 2026

Cell Population Analyses During Skin Carcinogenesis
06:53

Cell Population Analyses During Skin Carcinogenesis

Published on: August 21, 2013

13.0K
Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
11:10

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Published on: December 27, 2010

12.8K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.9K

Area of Science:

  • Pharmacology
  • Mycology
  • Clinical Pharmacy

Background:

  • Rezafungin (CD101) is a novel echinocandin antifungal agent.
  • It exhibits potent in vitro activity against Candida species, including resistant strains.

Purpose of the Study:

  • To develop a population pharmacokinetic (PK) model for rezafungin.
  • Characterize rezafungin disposition after intravenous administration.
  • Support dose selection for future clinical studies.

Main Methods:

  • Utilized data from two Phase 1 studies (single and multiple ascending dose).
  • Employed Monte Carlo parametric expectation maximization in S-ADAPT.
  • Developed a linear four-compartment model with allometric scaling for body weight.

Main Results:

  • The four-compartment model accurately described rezafungin plasma concentrations.
  • Allometric scaling for body weight was applied to PK parameters.
  • The model demonstrated excellent precision and minimal bias, accurately simulating observed data.

Conclusions:

  • The developed population PK model reliably characterizes rezafungin disposition.
  • The model can provide accurate concentration-time profiles.
  • This model will support dose selection for ongoing and future clinical trials.